Circadian Technologies is engaged in angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), the company seeks to develop truly novel therapies to extend and improve the lives of cancer sufferers. The company’s intellectual property rights include more than 50 patent families, 200 granted patents and 500 patents pending. The company’s most advanced program, VGX-100, an antibody-drug targeting VEGF-C, is expected to enter clinical trials in 2011. For further information, visit the company’s Web site at www.circadian.com.au

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: